Stay informed. See MDA updates on COVID-19

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

A Closer Look at Edasalonexent - A Potential New Treatment Option in Phase 3 Development for DMD

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Tuesday, September 1, 2020
Sponsor Information: 

This program is sponsored by Catabasis. This program is not sponsored, endorsed, or accredited by MDA.

Faculty

Erika Finanger, MD
Erika Finanger, MD
Associate Professor of Pediatrics - Division of Neurology - Oregon Health & Science University Hospital
Craig McDonald, MD
Craig McDonald, MD
Professor and Chair Department of Physical Medicine & Rehabilitation, Director of Neuromuscular Disease Clinics. Study Chair CINRG Duchenne Natural History Study, University of California
A Closer Look at Edasalonexent - A Potential New Treatment Option in Phase 3 Development for DMD
Activity Overview: 

In this webinar, Edasalonexent, an oral NF-κB inhibitor, is being evaluated in the global Phase 3 PolarisDMD Trial as a potential foundational therapy for all ambulatory boys affected by Duchenne muscular dystrophy, regardless of underlying mutation.